P2Y12 Inhibitors
SEE ALSO...
Items 1 to 10 of 17 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Farnesyl pyrophosphate ammonium salt, in methanol | 13058-04-3 | sc-364722 | 200 µg | $86.00 | ||
Farnesyl pyrophosphate ammonium salt in methanol exhibits unique interactions with the P2Y12 receptor, primarily through hydrophobic and ionic interactions that stabilize receptor conformation. This compound facilitates the activation of G-protein coupled pathways, leading to a cascade of intracellular signaling events. Its dynamic molecular structure allows for rapid binding kinetics, enhancing its efficacy in modulating receptor activity and influencing cellular signaling networks. | ||||||
Clopidogrel sulfate | 135046-48-9 | sc-337638A sc-337638 | 500 mg 1 g | $66.00 $139.00 | 2 | |
Clopidogrel sulfate acts as a potent modulator of the P2Y12 receptor, engaging in specific hydrogen bonding and hydrophobic interactions that promote receptor activation. Its unique stereochemistry allows for selective binding, influencing downstream signaling pathways. The compound exhibits notable reaction kinetics, characterized by a rapid association and slower dissociation, which enhances its ability to maintain receptor occupancy and modulate cellular responses effectively. | ||||||
POM 1 | 12141-67-2 | sc-203205 sc-203205A | 50 g 250 g | $163.00 $433.00 | 13 | |
POM 1 functions as a selective antagonist of the P2Y12 receptor, exhibiting unique molecular interactions that disrupt typical receptor activation. Its distinct conformational flexibility allows for competitive binding, altering the receptor's conformational landscape. The compound's kinetic profile reveals a fast initial binding phase followed by a prolonged interaction, effectively stabilizing the inactive receptor state and influencing downstream signaling cascades. | ||||||
Prasugrel Hydrochloride | 389574-19-0 | sc-208181 | 10 mg | $180.00 | ||
Prasugrel Hydrochloride acts as a potent P2Y12 receptor antagonist, characterized by its ability to form stable interactions with the receptor's binding site. This compound exhibits a unique mechanism of action through allosteric modulation, which alters receptor dynamics and inhibits platelet activation. Its rapid onset of action is complemented by a sustained effect, allowing for a prolonged influence on receptor signaling pathways, thereby impacting cellular responses. | ||||||
rac Clopidogrel-d4 Hydrogen Sulfate | 1219274-96-0 | sc-219816 | 1 mg | $306.00 | ||
Rac Clopidogrel-d4 Hydrogen Sulfate functions as a selective P2Y12 receptor antagonist, distinguished by its isotopic labeling that enhances tracking in metabolic studies. This compound engages in specific hydrogen bonding interactions with the receptor, influencing conformational changes that modulate downstream signaling pathways. Its kinetic profile reveals a unique rate of receptor binding and dissociation, providing insights into the dynamics of platelet activation and inhibition. | ||||||
Prasugrel | 150322-43-3 | sc-391536 | 100 mg | $77.00 | ||
Prasugrel acts as a potent P2Y12 receptor antagonist, characterized by its unique thiol group that facilitates covalent bonding with the receptor. This interaction leads to a stable, irreversible blockade, altering the receptor's conformation and inhibiting platelet aggregation. The compound exhibits distinct reaction kinetics, with a rapid onset of action and prolonged effects, highlighting its role in modulating cellular signaling pathways and enhancing understanding of thrombotic processes. | ||||||
Ticagrelor | 274693-27-5 | sc-472972 sc-472972A sc-472972B sc-472972C | 10 mg 25 mg 50 mg 100 mg | $102.00 $224.00 $265.00 $296.00 | ||
Ticagrelor is a non-thienopyridine, direct P2Y12 receptor antagonist. It reversibly binds to the P2Y12 receptor on platelets, inhibiting ADP-induced platelet aggregation. Unlike thienopyridines, ticagrelor does not require metabolic activation, providing a faster onset of action. It is used as an antiplatelet agent in research to prevent thrombotic events, particularly in patients with acute coronary syndrome. | ||||||
Prasugrel-d5 | 1127252-92-9 | sc-219635 | 1 mg | $380.00 | ||
Prasugrel-d5 is a selective P2Y12 receptor antagonist, distinguished by its deuterated structure, which enhances metabolic stability and alters pharmacokinetics. The incorporation of deuterium modifies the compound's isotopic profile, potentially influencing its interaction dynamics with the receptor. This results in unique binding affinities and altered reaction rates, providing insights into receptor-ligand interactions and the modulation of downstream signaling pathways in cellular processes. | ||||||
(±)-Clopidogrel hydrochloride | 90055-48-4 | sc-203553 sc-203553A | 10 mg 50 mg | $138.00 $587.00 | ||
(±)-Clopidogrel hydrochloride acts as a potent P2Y12 receptor antagonist, characterized by its unique thiophenyl group that facilitates specific interactions with the receptor's binding site. This compound undergoes metabolic activation, where its prodrug form is converted into an active metabolite, influencing the kinetics of platelet aggregation. The stereochemistry of clopidogrel plays a crucial role in its binding affinity, impacting the conformational changes within the receptor and subsequent signaling cascades. | ||||||
S-(+)-Clopidogrel Hydrogen Sulfate | 120202-66-6 | sc-220001 sc-220001A sc-220001B | 100 mg 1 g 5 g | $82.00 $165.00 $560.00 | 1 | |
S-(+)-Clopidogrel Hydrogen Sulfate is a selective P2Y12 receptor antagonist distinguished by its chiral configuration, which enhances its binding specificity. The compound's unique sulfonate group contributes to its solubility and stability in aqueous environments, facilitating effective receptor interaction. Its metabolic pathway involves enzymatic conversion, leading to a rapid onset of action. The compound's stereochemical properties significantly influence its interaction dynamics, modulating downstream signaling pathways. | ||||||